About Sichuan Cancer Hospital & Institute
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Sichuan Cancer Hospital and Research Institute
14
Hoffmann-La Roche
7
Jiangsu HengRui Medicine Co., Ltd.
2
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2
BeiGene
1
Betta Pharmaceuticals Co., Ltd.
1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
1
Celgene
1
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
1
Hanmi Pharmaceutical Company Limited
1
Clinical Trials at Sichuan Cancer Hospital & Institute
During the past decade, Sichuan Cancer Hospital & Institute conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 1 clinical trials were completed, i.e. on
average, 2.8% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 1 clinical trials were completed. i.e. 3.6%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）
2014-01-01
2020-10-01
Unknown status
420
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
2014-04-01
2020-07-01
Unknown status
100
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
2014-09-01
2017-10-01
Completed
222
A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
2016-04-01
2017-12-01
Unknown status
4,200
A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
2018-12-01
2020-01-01
Withdrawn
0
Perioperative Symptom Study of Lung Cancer (CN-PRO-Lung 1)
2017-11-21
2020-01-01
Completed
512
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
2019-05-22
2019-06-26
Terminated
1
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
2019-06-10
2023-04-01
Active, not recruiting
543
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Sichuan Cancer Hospital & Institute" #1 sponsor was "Sichuan Cancer Hospital and Research Institute" with 14 trials, followed by "Hoffmann-La Roche" with 7 trials
sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 2 trials sponsored, "Suzhou Suncadia Biopharmaceuticals Co., Ltd." with 2 trials sponsored and "BeiGene"
with 2 trials sponsored. Other sponsors include 8 different institutions and
companies that sponsored additional 18 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Sichuan Cancer Hospital & Institute"
#1 collaborator was "Hebei Medical University Fourth Hospital" with 2 trials as a collaborator, "Jiangyou People's Hospital" with 2 trials as a collaborator, "Peking University Cancer Hospital & Institute" with 2 trials as a collaborator, "Affiliated Cancer Hospital & Institute of Guangzhou Medical University" with 1 trials as a collaborator and "Affiliated Hospital of Southwest Medical University" with 1 trials as a collaborator. Other collaborators include 27 different institutions and companies that were
collaborators in the rest 37 trials.
Clinical Trials Conditions at Sichuan Cancer Hospital & Institute
According to Clinical.Site data, the most researched conditions in "Sichuan Cancer Hospital & Institute" are
"Esophageal Squamous Cell Carcinoma" (6 trials), "Breast Cancer" (3 trials), "NSCLC" (3 trials), "Hepatocellular Carcinoma" (2 trials) and "Non-small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Sichuan Cancer Hospital & Institute" in a lesser frequency.
Clinical Trials Intervention Types at Sichuan Cancer Hospital & Institute
Most popular intervention types in "Sichuan Cancer Hospital & Institute" are "Drug" (30 trials), "Radiation" (8 trials), "Combination Product" (3 trials), "Other" (3 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (6 trials), "Placebo" (6 trials), "Cisplatin" (4 trials), "Carboplatin" (3 trials) and "Chemotherapy" (3 trials). Other intervention names were less common.
Clinical Trials Genders at Sichuan Cancer Hospital & Institute
The vast majority of trials in "Sichuan Cancer Hospital & Institute" are
38 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Sichuan Cancer Hospital & Institute
Currently, there are 24 active trials in "Sichuan Cancer Hospital & Institute".
3 are not yet recruiting,
14 are recruiting,
6 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 4 completed trials in Sichuan Cancer Hospital & Institute,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Sichuan Cancer Hospital & Institute, 2 "Phase 1"
clinical trials were conducted, 14 "Phase 2" clinical
trials and 19 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 2 trials that are defined as “Not Applicable".